A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
AllAfrica on MSN2d
A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major ConferenceA single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Spotlight reports on this and some of the ...
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...
The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...
Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human ...
The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...
HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the ...
JPMorgan says that while the Wall Street Journal’s report on potential Centers for Disease Control and Prevention funding cuts for HIV ...
A main obstacle to an HIV cure is that viral DNA integrates into the chromosomes of memory T cells (blue), which evade ...
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback